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Background: We aimed to determine the smallest changes in health-related quality of life (HRQoL) scores in the
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 and the Brain
Cancer Module (QLQ-BN20), which could be considered as clinically meaningful in brain cancer patients.
Materials and methods: World Health Organisation performance status (PS) and mini-mental state examination
(MMSE) were used as clinical anchors appropriate to related subscales to determine the minimal clinically important
differences (MCIDs) in HRQoL change scores (range 0–100) in the QLQ-C30 and QLQ-BN20. A threshold of 0.2
standard deviation (SD) (small effect) was used to exclude anchor-based MCID estimates considered too small to
inform interpretation.
Results: Based on PS, our findings support the following integer estimates of the MCID for improvement and
deterioration, respectively: physical (6, 9), role (14, 12), and cognitive functioning (8, 8); global health status (7, 4*),
fatigue (12, 9), and motor dysfunction (4*, 5). Anchoring with MMSE, cognitive functioning MCID estimates for
improvement and deterioration were (11, 2*) and for communication deficit were (9, 7). Estimates with asterisks were
<0.2 SD and were excluded from our MCID range of 5–14.
Conclusion: These estimates can help clinicians evaluate changes in HRQoL over time, assess the value of a health
care intervention and can be useful in determining sample sizes in designing future clinical trials.
Key words: anchoring, deterioration, EORTC QLQ-C30, health-related quality of life, improvement, minimal clinically
important difference
introduction
The increasingly frequent use of patient-reported health-related
quality of life (HRQoL) as an outcome in cancer clinical trials
over the years implies a greater need for meaningful
interpretations of aggregated HRQoL scores. Determining the
minimal clinically important difference (MCID) [1] for
HRQoL scores from cancer clinical trials is useful to clinicians,
patients, and researchers as a benchmark for assessing the
effectiveness of a health care intervention and for determining
the sample size in a clinical trial. Benchmarks for interpreting
differences between groups cross-sectionally may differ from
those for interpreting changes over time within groups [2]. It is
important to determine the MCID for HRQoL outcomes
because statistical significance based on, e.g. P values, does not
provide information about the clinical meaningfulness. In large
sample sizes, statistically significant results can be obtained
when numerical differences in HRQoL change scores are small
and not likely to be clinically meaningful. Furthermore, as more
and more studies examine the MCIDs for differing
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questionnaires and cancers, it will become evident whether it is
possible to generalize and adopt one MCID or a set of MCIDs
for all questionnaires and patient groups. It will take a large
number of such explorations to increase the confidence and
familiarity of investigators. Thus, every study contributing to
this question is important.
Investigators have relied on two distinct approaches for
identifying the MCID: the anchor-based and distribution-based
[3]. Anchor-based methods link HRQoL measures to external
criteria, either to a known indicator that has clinical relevance [e.g.
progression of disease, performance status (PS), etc.] or to
patient-derived ratings of change in health [1, 3]. Distribution-
based approaches hinge on the statistical features of the HRQoL
data. Commonly used approaches include fractions of the
standard deviation (SD) [4] of HRQoL scores, the effect size [5],
and standard error of measurement (SEM) [6]. Differences of
0.2 SD [4] or 0.3 SD [7] have been used to estimate the MCID.
Some authors suggest that 0.5 SD is a reasonable approximation
for theMCID[8], although others feel that this is not generalizable
[9, 10]. Thresholds of 1 SEM have also been suggested [11]. Other
investigators, using data from patients’ ratings of their own global
change [12] or frompatients’ comparisons of themselves to others
[13], determined that 5%–10%of the instrument range represents
a subjectively significant difference or clinically significant change.
The European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire core 30 (EORTC
QLQ-C30) assesses HRQoL in cancer patients with 15 scales,
each ranging in scores from 0 to 100. The EORTC Brain Cancer
Module (EORTC QLQ-BN20), which is intended to
supplement the QLQ-C30 when assessing HRQoL, assesses
disease symptoms, side-effects of treatment, and some specific
psychosocial issues of importance to patients with brain cancer
using four scales and seven single items, also ranging in scores
from 0 to 100. Anchor-based methods have been used
previously to aid the interpretation of QLQ-C30 scores [12,
14]. Using global ratings of change as the anchor, Osoba et al.
[12] suggested that in patients with breast and small-cell lung
cancer, changes in scores of 5–10 represented a small difference;
10–20 represented a moderate difference while those above 20
represented large differences. Using a variety of clinical
classifications as anchors, King [14] came to similar findings
after collating results from various studies and various cancer
sites. Based on these two studies, mean differences of 10 points
or more are widely viewed as being clinically significant when
interpreting the results of randomized clinical trials that use the
QLQ-C30 [15]. However, the evidence is not clear that a
10-point threshold is applicable to each of the 15 QLQ-C30
scales [15]. Furthermore, it has not yet been established
whether the same thresholds apply to improvement and
deterioration in HRQoL scores. These thresholds may also vary
across patient groups. Additional empirical investigation of the
size and patterns of MCIDs across domains of the QLQ-C30 in
specific patient groups is therefore justified. No MCIDs have
been determined yet for either the QLQ-C30 in brain cancer or
the QLQ-BN20.
The main focus of this study was to determine the change in
selected QLQ-C30 and QLQ-BN20 scales, which corresponds to
the MCID for improvement and deterioration in HRQoL for
brain cancer patients. Identification of MCIDs was carried out
using two clinical anchors: change in physician-rated World
Health Organisation (WHO) PS and changes in the mini-
mental state examination (MMSE).
patients and methods
the EORTC QLQ-C30 and the QLQ-BN20
The QLQ-C30 contains both single- and multi-item scales. Of the 30 items,
24 aggregate into nine multi-item scales representing various HRQoL
dimensions: five functioning scales (physical, role, emotional, cognitive and
social), three symptom scales (fatigue, pain and nausea), and one global
measure of health status. The remaining six single-item scales assess
symptoms: dyspnea, appetite loss, sleep disturbance, constipation and
diarrhea, and the perceived financial impact of the disease treatment. High
scores indicate better HRQoL for the global health status and functioning
scales, and worse HRQoL for the symptom scales. The QLQ-BN20 contains
20 items, 13 of which aggregate into four scales assessing future uncertainty,
visual disorder, motor dysfunction (MD), and communication deficit.
The remaining single items assess other disease symptoms (e.g. headaches
and seizures) and treatment toxic effects (e.g. hair loss) [16]. For all
these scales, a higher score represents worse HRQoL.
description of the data
Two closed EORTC randomized controlled clinical trials (RCTs) enrolling
in total 941 high-grade glioma patients were jointly analyzed. Trial 1
reported by Stupp et al. [17] compared radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone, enrolled 573 patients
and used the EORTC QLQ-C30 version 3. Trial 2 reported by van den Bent
et al. [18] was an RCT comparing radiation therapy with and without
combination chemotherapy, which enrolled 368 patients and used version 2
of the EORTC QLQ-C30. These two versions of the QLQ-C30 differ only in
the response options for the items in the physical and role functioning
domains. Version 2 uses a binary (no, yes) scale and version 3 uses a
4-point scale ranging from ‘not at all’ to ‘very much’ [19]. Analysis
pertaining to physical and role functioning scales was restricted to Trial 1,
which used version 3, the current version [19]. In both trials, HRQoL was
measured as a secondary end point at baseline, during treatment, and on
several follow-up occasions after the end of treatment.
the anchors and selection of QLQ-C30 scales
The anchor-based approach to developing MCIDs requires an independent
standard or ‘anchor’ that is itself interpretable and at least moderately
correlated with the instrument being explored [20]. The WHO PS and the
MMSE were chosen as the clinical anchors against which changes in selected
scales of the QLQ-C30 and QLQ-BN20 would be calibrated. These anchors
are clearly definable, understandable, and are commonly used by clinicians
in assessment of cancer patients and could therefore help guide
interpretation of HRQoL scores. The values for WHO PS range from 0 (no
symptoms of cancer) to 4 (bedbound). Changes in PS were categorized
into three groups: deterioration (PS worsened by one category), no change
(PS stayed the same), and improvement (PS improved by one category).
The MMSE [21] is a test with a 30-point maximum score, which is used to
screen for cognitive impairment. Any score ‡25 points (out of 30) is
effectively normal. Changes in MMSE were grouped as: deterioration
(MMSE worsened by 4 or 5 points), no change (MMSE changed by 3 or less
points), and improvement (MMSE improved by 4 or 5 points). Changes in
MMSE of 4 or more points have been considered in the literature as
clinically significant [22, 23]. In this study, changes in MMSE of 6 or more
points were viewed as rather too large for the purpose of determining the
MCID and were therefore excluded from the analysis, as were the changes
in PS of two or more categories in order not to overestimate the MCID.
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We conducted MCID analyses only for those scales from the QLQ-C30
and QLQ-BN20 that were expected to be clinically related to the anchors
and had a correlation of at least 0.30 with the anchors at baseline [24].
Scales from the QLQ-C30 that were suitable for anchoring against PS,
together with the respective correlation coefficients with the anchor were:
cognitive functioning (CF, 20.31), physical functioning (PF, 20.40), role
functioning (RF, 20.40), global health status (GHS, 20.32), and fatigue
(FA, 0.34). The MD scale of the QLQ-BN20 had a correlation of 0.41 with
PS and was also anchored against PS. Only two scales were suitable for
anchoring with the MMSE: cognitive functioning (CF, 0.35) from the QLQ-
C30 and communication deficit (CD, 0.41) from the QLQ-BN20.
analysis
Our focus was on changes in individual HRQoL scores of patients over
time, anchoring by changes in WHO PS and changes in the MMSE,
respectively. Separate analyses were conducted for these two anchors. For
each analysis, patients with data on an anchor and HRQoL scores at 2 or
more time points were included. The two points furthest apart in time,
denoted by T1 and T2, provided a better chance of observing changes in
HRQoL scores and were therefore used for analysis.
Changes in the anchor values and HRQoL scores between T1 and T2 were
calculated for each patient. Each individual patient’s HRQoL change score
was assigned to one of the three ‘clinically meaningful’ categories, as defined
a priori by the anchors, e.g. ‘improvement’, ‘no change’, and ‘deterioration’
groups for PS, similarly for MMSE. Note that patients could be categorized
differently between the anchor and HRQoL measures, e.g. some patients
could be classified as having not changed according to the anchor yet their
change in HRQoL was not 0, and if this occurred systematically in one
direction, the mean HRQoL change for this category would deviate from
the expected value of 0. Therefore, to control for the amount of change in
HRQoL that occurred to patients who did not change according to the
anchor, we obtained estimates of the MCID by calculating the difference in
mean HRQoL change between adjacent categories [11], i.e. ‘improvement’
versus ‘no change’ and ‘no change’ versus ‘deterioration’. Ninety-five
percent confidence intervals (CI) for the differences in mean of change
scores between adjacent categories (the MCID) were calculated.
The association between HRQoL scores and anchor values and between
changes in the anchor values and changes in the HRQoL scale were
quantified by the Spearman’s rank correlation coefficient.
For comparison purposes, four distribution-based approaches were
applied: 0.2 SD, 0.3 SD, 0.5 SD, and the SEM. Each of these statistics
was calculated twice, once with an estimate of SD from T1 and again with
an estimate of SD from T2. The calculation of the SEM also requires an
estimate of test–retest reliability, which we obtained from previous studies
for the QLQ-BN20 [16] and the QLQ-C30 [25]. Our MCID results were
also compared with the 5%–10% range of the instrument [13].
results
Table 1 summarizes selected baseline demographic and clinical
characteristics in the combined sample of all the 941 patients
from the two trials.
Descriptive statistics summarizing the distributions of
HRQoL scores at baseline are given in Table 2. The
distributions for PF, RF, CF, MD, CD, and FA were skewed,
with a predominance of good functioning and communicating
ability, and low fatigue and MD, while GHS appeared
reasonably symmetrical.
Fifteen patients improved their MMSE by 6 or more points
and 33 patients deteriorated by 6 or more points and were
excluded from further MMSE analyses. Excluded from the PS
analyses were two patients whose PS deteriorated by two
categories and 51 patients whose PS improved by two or more
categories.
The cross-sectional correlations of HRQoL measures with PS
were generally moderate, ranging in absolute value from 0.31 to
0.51 (Table 2). The correlations between changes in HRQoL
scores and changes in PS were generally weak, ranging from
0.13 to 0.24 in absolute value. Cross-sectional correlations
between MMSE and CF at T1 and T2 were 0.30 and 0.34,
respectively, while for changes in CF and MMSE, the
correlation was 0.24. Cross-sectional correlation between
MMSE and CD at both times was 0.30 and for the changes,
the correlation was 0.15.
The mean change scores for the selected QLQ-C30 and QLQ-
BN20 scales and corresponding differences between adjacent
categories are presented in Tables 3 and 4, anchored by PS and
MMSE, respectively.
MCID estimates anchored by PS are given in Table 3. For
illustration, the first difference in PF mean change of adjacent
categories is obtained as 4.32(21.3) = 5.6 PF units, and the
second is calculated as 21.32(29.8) = 8.5 PF units, providing
the MCID estimates for improvement and deterioration,
respectively. The 95% CI for PS-anchored MCIDs generally did
not include zero, suggesting statistically significant differences
Table 1. Selected baseline demographic and clinical characteristics of the
patients
Descriptive statistics Number (%)
Gender
Male 572 (61.0)
Female 368 (39.0)
Performance status
0 357 (38.0)
1 448 (48.0)
2 131 (14.0)
Country
Australia 3 (0.3)
Austria 32 (3.4)
Belgium 57 (6.1)
Canada 168 (17.8)
Finland 6 (0.6)
France 153 (16.3)
Germany 79 (8.4)
Hungary 10 (1.1)
Israel 14 (1.5)
Italy 81 (8.6)
Poland 3 (0.3)
Slovenia 3 (0.3)
Spain 19 (2.0)
Sweden 10 (1.1)
Switzerland 52 (5.5)
The Netherlands 208 (22.1)
UK 43 (4.6)
Age (n = 941)
Mean (years) 52
Interquartile range (years) 45–61
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between the mean change of adjacent categories except for
the ‘improvement’ and ‘no change’ comparison for PF and
MD and the ‘no change’ and ‘deterioration’ comparison for
GHS. In the MCID estimates for CF and CD anchored by
MMSE (Table 4), statistically significant differences were noted
only between the ‘improvement’ and ‘no change’ groups.
Table 5 presents distribution-based MCID estimates for
comparison with anchor-based estimates in Tables 3 and 4.
Since the results for T1 and T2 were very similar, only the results
at T1 are reported.
discussion
The aim of our analysis was to determine the magnitude of
difference in scores on selected QLQ-C30 and QLQ-BN20
scales that represents the MCID in brain cancer patients. We
used WHO PS as a clinical anchor to determine the MCID
estimates for QLQ-C30 scales: physical, role, and cognitive
functioning, global health status, fatigue and for MD from the
QLQ-BN20. The MMSE was used as an anchor for the QLQ-
C30 cognitive functioning scale and the QLQ-BN20
communication deficit scale. To further clarify the issue of
MCIDs, the findings from the anchor-based approach were
compared with selected distribution-based techniques.
Our analysis combined data from two versions of the QLQ-
C30 where one version used a 4-point scale and the other a
binary scale. The two versions differ only in the response
options for items in the physical and role functioning domains.
The 4-point and binary scales are not comparable, and
therefore, combining data for the physical and role functioning
domains may not be appropriate. In light of this, we restricted
analysis of physical and role functioning domains only to the
most recent version of the questionnaire; the one that uses the
4-point scale.
In general, the mean changes in HRQoL within each anchor-
defined category were in the expected direction. Patients
classified as having improved by the anchor tended to have
better HRQoL scores, and those classified as deteriorated by the
anchor tended to have worse HRQoL scores, while those
classified as not changed by the anchor generally did not appear
to have changed in their HRQoL (i.e. mean change in HRQoL
was roughly 0).
Our results suggest that the MCID estimates for
improvement and for deterioration tend to vary across the
selected QLQ-C30 and QLQ-BN20 scales. However, we found
no clear indication that the MCID for improvement was
systematically larger or smaller than the MCID for
deterioration. This is in contrast to a number of studies [12, 13,
26] that have found that MCID estimates for deterioration were
larger than those for improvement. Further investigation, if
possible with other anchors, is therefore recommended.
In general, the anchor-based MCID estimates tended to be
larger than the 0.2 SD estimates, smaller than the 0.5 SD
estimates, and closer to both the 0.3 SD and SEM. This
provides further evidence that the 0.5 SD may represent a
‘medium’ effect size [5], whereas the 1 SEM [6] and 0.3 SD [7]
may approximate a threshold for defining the MCID. The range
of anchor-based MCID estimates of 5–14 points is in line with
the 5%–10% range of the instrument (5–10 points) [12, 13],
which was considered as a subjectively significant difference or
clinically significant change.
We acknowledge as a limitation that the observed
correlations between the anchors and HRQoL scores were not
strong. It may therefore be argued that such anchors may not
be used for the particular scales. Other studies [12, 13] have
also found only moderately strong correlations of the anchors
with the HRQoL scores; the reason(s) are unknown. For
interpretation, it could be recommended to augment the
anchor-based MCID estimates with results from one of the
distribution-based approaches by considering only those
anchor-based MCID estimates at least equal to 0.2 SD [11],
which is a ‘small effect’ [5]. This would then imply that the
MCID estimates for deterioration for global health status
(Table 3) and cognitive functioning (based on MMSE, Table 4)
and that for improvement for MD (Table 3) will not be
recommended as plausible MCID estimates.
In an anchor-based approach, it is critical that the anchors be
understandable and clinically significant. Changes in PS are
accepted as clinically significant by most oncologists, and PS
criteria is frequently used to determine eligibility for a given
treatment or clinical trial. Furthermore, the changes that we are
calling MCIDs are based on the definitions and clinical anchors
that we have applied, e.g. a one category change on a 5-point
WHO PS scale. Had we used a one-category change in the
Table 2. Summary statistics for HRQoL scales at baseline, cross-sectional correlation estimates for HRQoL scores with PS, and correlations between
HRQoL change scores with changes in the anchor
HRQoL summary statistics at baseline Cross-sectional correlation (HRQoL and PS) Correlation between changes
in HRQoL and changes in PS
Mean (SD) Median Q1 Q3 T1 T2
PF 78.8 (25.0) 86.7 66.7 100 20.40 20.51 20.21
RF 60.7 (33.8) 66.7 33.0 100 20.41 20.47 20.21
CF 71.5 (27.6) 83.3 50.0 100 20.35 20.39 20.19
GHS 62.1 (22.8) 66.7 50.0 83.3 20.33 20.39 20.13
FA 36.3 (24.8) 33.3 22.2 55.6 0.31 0.43 0.24
MD 17.6 (22.5) 11.1 0.0 22.2 0.42 0.46 0.14
CD 17.6 (24.7) 11.1 0.0 33.3
Q1 and Q3 are the lower and upper quartiles. CD was not anchored against PS and correlations with PS are therefore not presented.
HRQoL, health-related quality of life; PS, performance status; PF physical functioning; RF, role functioning; CF, cognitive functioning; GHS, global health
status; FA, fatigue; MD, motor dysfunction; CD, communication deficit; SD, standard deviation.
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10-point Karnofsky performance scale, our results would
probably differ. In other words, the MCIDs we have found are
not ‘absolute’ but are ‘relative’ to the clinical anchors we used.
Another limitation with our study is the limited availability
of other appropriate anchors. Being retrospective in nature, our
analysis was restricted to use only WHO PS and MMSE, which
were deemed credible anchors for the selected scales.
Determination of the MCID based on a number of different
anchors would be the preferred approach.
In conclusion, our findings provide estimates of MCIDs for
brain cancer patients when using the EORTC QLQ-C30. The
estimates generally agree with the estimates of 5–10 units of
the QLQ-C30 scales we considered and as proposed by Osoba
et al. [12] and King [14]. These estimates can be useful to
clinicians to determine the proportion of patients benefiting
from some treatment. The estimates could also be used as
guidance for classification of patients by changes in HRQoL
and symptoms over time. Furthermore, the estimates may be
useful in sample size determination and design for future
clinical trials.
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Table 5. Distribution-based MCID estimates at T1
Scale Distribution-based method
0.2 SD 0.3 SD 0.5 SD SEM
PF 5.1 8.6 12.9 7.7
RF 6.7 11.1 16.7 14.2
CF 5.3 8.9 13.3 11.3
GHS 4.4 7.4 11.0 9.4
FA 4.8 8.0 12.1 10.0
MD 4.5 7.4 11.1 10.0
CD 4.5 7.5 11.2 13.0
SD, standard deviation; SEM, standard error of measurement; PF physical
functioning; RF, role functioning; CF, cognitive functioning; GHS, global
health status; FA, fatigue; MD, motor dysfunction; CD, communication
deficit.
Table 3. Performance status—mean (SD) of HRQoL change scores in the three anchor-defined groups and the MCID (95% CI) between adjacent
categories
Scale Improved by one category,
n (32–85)
No change,
n (168–324)
Deteriorated by
one category, n (67–163)
MCID (95% CI)
Difference in mean change between adjacent categories
Improvement Deterioration
PF 4.3 (25.6) 21.3 (20.3) 29.8 (23.7) 5.6 (22.4 to 13.7) 8.5 (2.4 to 14.5)*
RF 18.7 (28.8) 4.4 (35.1) 27.9 (32.3) 14.3 (1.5 to 27.1)* 12.3 (2.6 to 21.8)*
CF 6.8 (26.3) 20.8 (25.1) 29.0 (27.7) 7.6 (1.3 to 14.7)* 8.2 (3.2 to 14.1)*
GHS 8.8 (28.4) 1.5 (24.1) 22.0 (22.3) 7.3 (1.0 to 13.6)* 3.5 (21.0 to 8.0)
FA 212.8 (26.3) 20.4 (26.6) 8.5 (27.7) 212.4 (219.0 to 25.9)* 28.9 (214.0 to 23.7)*
MD 24.5 (24.7) –0.2 (20.0) 5.0 (20.3) 24.3 (29.6 to 1.1) 25.2 (29.0 to 21.3)*
PF and RF are based on trial 1 only. The number of patients in the anchor-defined groups varies by the HRQoL scale and is therefore presented as a range of
values for all the scales. Differences that are statistically significant are indicated by asterisk. Difference in mean change refers to the difference in mean of
HRQoL change scores between the ‘Improvement’ and ‘no change’ (Improvement) and between the ‘no change and ‘deterioration’ (Deterioration).
HRQoL, health-related quality of life; MCID, minimum clinically important difference; CI, confidence interval; PF physical functioning; RF, role functioning;
CF, cognitive functioning; GHS, global health status; FA, fatigue; MD, motor dysfunction.
Table 4. MMSE—mean (SD) of HRQoL change scores in the three anchor-defined groups and the MCID (95% CI) between adjacent categories
Scale Improved by 4 or 5
points, n (26)
No change,
n (371)
Deteriorated by
4 or 5 points, n (23)
MCID (95% CI)
Difference in mean change between adjacent categories
Improvement Deterioration
CF 9.0 (22.7) 21.8 (25.1) 23.6 (28.0) 10.8 (0.9 to 20.8)* 1.8 (28.9 to 12.4)
CD 25.7 (19.2) 3.4 (20.2) 10.4 (21.7) 29.1 (216.7 to 21.5)* 27.0 (215.6 to 1.5)
Differences that are statistically significant are indicated by asterisk. Difference in mean change refers to the difference in mean of HRQoL change scores
between the ‘Improvement’ and ‘no change’ (Improvement) and between the ‘no change and ‘deterioration’ (Deterioration).
MMSE, mini-mental state examination; HRQoL, health-related quality of life; MCID, minimum clinically important difference; CI, confidence interval; CF,
cognitive functioning; CD, communication deficit.
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